How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Liver Disease

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2013.07.014PMID 24099029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute and Acute Severe (Fulminant) Autoimmune Hepatitis

  2013cited by this paper
• The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers

  2012cited by this paper
• Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin

  2012cited by this paper
• Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

  2011cited by this paper
• Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

  2011cited by this paper
• Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

  2011cited by this paper
• Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.

  2011cited by this paper
• Risk factors for idiosyncratic drug-induced liver injury.

  2010cited by this paper
• Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994.

  2009cited by this paper
• Serum Aminotransferases after Low-Dose Heparin Treatment

  2009cited by this paper
• Drug-induced liver injury following positive drug rechallenge.

  2009cited by this paper
• Aetiology and outcome of acute liver failure.

  2009cited by this paper
• Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury

  2008cited by this paper
• The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study.

  2007cited by this paper
• Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.

  2007cited by this paper
• Liver injury in long‐term methotrexate treatment in psoriasis is relatively infrequent

  2006cited by this paper
• Drug-related hepatotoxicity.

  2006cited by this paper
• Hy's law: predicting serious hepatotoxicity

  2006cited by this paper
• Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.

  2006cited by this paper
• Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

  2005cited by this paper
• Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

  2005cited by this paper
• Outcome and prognostic markers in severe drug‐induced liver disease

  2005cited by this paper
• Drug hepatotoxicity.

  2002cited by this paper
• Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity

  2001cited by this paper
• Drug-induced liver disease.

  2000cited by this paper
• Drug-induced liver disease.

  2000cited by this paper
• A prospective study of the causes of notably raised aspartate aminotransferase of liver origin

  1999cited by this paper
• Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

  1999cited by this paper
• Bromfenac(Duract)-associated hepatic failure requiring liver transplantation

  1999cited by this paper
• Thrombotic Thrombocytopenic Purpura after Ecstasy-Induced Acute Liver Failure

  1999cited by this paper
• Severe hepatotoxicity associated with bromfenac sodium

  1999cited by this paper
• Fatal Fulminant Hepatitis Associated with Bromfenac Use

  1999cited by this paper
• Rating the Rating Scales

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group.

  1999cited by this paper
• Schiff's diseases of the liver

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation

  1999cited by this paper
• Fatal hepatotoxicity associated with troglitazone.

  1998cited by this paper
• Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone

  1998cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis

  1997cited by this paper
• Histopathologic changes associated with fialuridine hepatotoxicity.

  1997cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper
• Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.

  1994cited by this paper
• Prevalence of hepatitis C virus RNA in suspected drug induced liver diseases.

  1993cited by this paper
• Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

  1993cited by this paper
• Hypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated Hepatitis

  1992cited by this paper
• Drug-induced liver disease

  1990cited by this paper
• Drug-induced liver disease.

  1989cited by this paper
• Ticrynafen‐Associated Hepatic Injury: Analysis of 340 Cases

  1984cited by this paper
• Transaminase elevations in patients receiving bovine or porcine heparin.

  1984cited by this paper
• Hepatotoxicity associated with ticrynafen--a uricosuric diuretic.

  1982cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Serum aminotransferases after low-dose heparin treatment. Short communication.

  1978cited by this paper
• Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.

  1975cited by this paper

• Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use

  2023influential citation
• Towards 3D-bioprinted Models of the Liver to Boost Drug Development.

  2022cites this paper
• Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring

  2020cites this paper
• Drug-Induced Liver Injury (DILI): Current status and future directions for drug development and the post-market setting

  2020cites this paper
• Drug-Induced Liver Injury in Children

  2018cites this paper
• Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

  2018cites this paper
• Assessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting Database

  2017cites this paper
• Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury.

  2017cites this paper
• Biomarkers in Nonclinical Drug Development

  2017cites this paper
• Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

  2016cites this paper
• Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action

  2016cites this paper
• Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.

  2015cites this paper
• Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

  2015cites this paper
• Hepatocyte-Based Metabolism, Drug–Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition

  2015cites this paper
• Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOCTM) System

  2015influential citation
• Gauging reactive metabolites in drug-induced toxicity.

  2014cites this paper
• Evaluation of In Situ Generated Valproyl 1-O-β-Acyl Glucuronide in Valproic Acid Toxicity in Sandwich-Cultured Rat Hepatocytes

  2014cites this paper
• Biomarkers and human hepatocytes.

  2014cites this paper
• In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.

  2014cites this paper
• Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.

  2014cites this paper
• Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury.

  2014cites this paper
• Valproic Acid Toxicity in Sandwich-Cultured Rat Hepatocytes

  2014cites this paper
• Valproic acid biotransformation and toxicity in sandwich-cultured rat hepatocytes

  2014influential citation